Acumen Pharmaceuticals, Inc.

ABOS

$3.11

+0.49%

2026-09-04 12:37:40 EDT+$0.02

Healthcare

Biotechnology

NASDAQ

Active Trading

Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's ...

Price Action of ABOS

$3.11

+0.49%+$0.02

High—

Low—

52W High-13.6%

Rel. vol—

Interval

Range15m

Volume—SMA5SMA10

—

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company singularly focused on developing novel therapeutics for Alzheimer's disease (AD), a devastating neurodegenerative condition. The company was founded in 1996 based on pioneering research into the role of toxic soluble amyloid-beta oligomers (AβOs) in AD pathology. Acumen's lead drug candidate, ACU193, is ...Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company singularly focused on developing novel therapeutics for Alzheimer's disease (AD), a devastating neurodegenerative condition. The company was founded in 1996 based on pioneering research into the role of toxic soluble amyloid-beta oligomers (AβOs) in AD pathology. Acumen's lead drug candidate, ACU193, is an investigational humanized monoclonal antibody designed to selectively bind and neutralize AβOs, which are believed to be the most neurotoxic forms of amyloid-beta. ACU193 is currently being evaluated in Phase I clinical trials for safety and tolerability, with potential to slow or halt disease progression. Beyond ACU193, Acumen is building a pipeline of therapies targeting AβOs and other mechanisms relevant to AD, leveraging decades of research. The company has a strong scientific foundation, with co-founders including William Klein, a leading researcher in AβO biology. Under the leadership of CEO Daniel O'Connell, Acumen has raised substantial funding, including an IPO in 2021, and maintains a strong balance sheet with cash and equivalents of approximately $2.03 per share. Financially, the company is pre-revenue, with all resources invested in R&D, leading to negative operating cash flows and net losses typical of biotech firms. Employee count is around 60, with a small but dedicated team. Acumen partners with academic institutions and CROs to advance its programs. The company's long-term vision is to deliver safe and effective treatments for AD, addressing an enormous unmet need. With strategic focus on AβOs, Acumen aims to differentiate itself from other AD therapies by targeting the most toxic species. Future milestones include Phase I data readouts and potential advancement to later-stage trials. Overall, Acumen represents a scientifically driven, high-risk/high-reward investment in the fight against Alzheimer's.ExpandCollapse

Founded

1996

Employees

CEO

Daniel J. O'Connell

Full Name

Acumen Pharmaceuticals, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-136.27%

Market Cap

$0.22B

Current Ratio

2.47

WACC

7.16%

ROIC

-146.64%

Contact Information

https://acumenpharm.com

434 297 1000

1210-1220 Washington St., Newton, MA 02465

Key Metrics of ABOS

Snapshot

Latest / TTM · 6 periods

Market Cap

$224.55M

ROCE

-152.4%

EV / EBITDA

-1.95x

-19.0% YoY

FCF Yield

-41.1%

+49.4% YoY

Cash Conversion Cycle

-106159.5d

Current Ratio

2.47

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of ABOS

Profitability trend

Latest / TTM · 6 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-1.88x

n/a

Debt / Equity

0.55

n/a

Current Ratio

2.47

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of ABOS

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.38 · Revenue $0.00 · 2 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.36 · Revenue $0.00 · 2 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-1.53 · Revenue $0.00 · 3 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.30 · Revenue $0.00 · 1 analysts

Recent history

Aug 12, 2026
Q2 FY2026 · Results reported
EPS $-0.45 · Revenue $0.00
View filing
May 12, 2026
Q1 FY2026 · Results reported
EPS $-0.33 · Revenue $0.00
View filing
Mar 26, 2026
FY2025 · Annual results
EPS $-2.00 · Revenue $0.00
View filing
Nov 12, 2025
Q3 FY2025 · Results reported
EPS $-0.44 · Revenue $0.00
View filing
Aug 12, 2025
Q2 FY2025 · Results reported
EPS $-0.68 · Revenue $0.00
View filing
May 13, 2025
Q1 FY2025 · Results reported
EPS $-0.48 · Revenue $0.00
View filing

Financial Statements of ABOS

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$0	—	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-121.3M	-18.6%	-57.8%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	—	—	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	—	—	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	—	—	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-115.6M	-34.1%	+25.1%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	—	—	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	44.5%	+172.1%	+54.8%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	4.07x	-36.9%	-45.9%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$122.8M	-48.6%	-13.2%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-2.00 vs -2.05	+2.3%	-0.45 vs -0.36	-25.2%
Revenue Surprise	—	—	—	—

Insider Transactions of ABOS

Acquisitions (A)

Since Jun 3, 2026

Disposals (D)

Since Jun 3, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jun 17, 2026	Porter Derrell	director	Common Stock	A	13,040	$1.07
Jun 17, 2026	Porter Derrell	director	Common Stock	D	13,040	$2.33
Jun 17, 2026	Porter Derrell	director	Stock Option (right to buy)	D	13,040	$1.07
Jun 16, 2026	Porter Derrell	director	Common Stock	D	12,800	$2.33
Jun 15, 2026	Porter Derrell	director	Common Stock	A	6,460	$1.07

Earnings Call Transcript of ABOS

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Good day, and welcome to the Acumen Pharmaceuticals Second Quarter 2026 Conference Call and Webcast. [Operator Instructions] Please note this call is being recorded. I would like to turn the call over to Alex Braun, Head of Investor Relations. Please go ahead. Alex Braun: Thanks, Michelle. Good morning, and welcome to the Acumen conference call to discuss our business update and financial results for the quarter ended June 30, 2026. With me today are Dan O'Connell, our Chief Executive Officer, and Matt Zuga, our CFO and Chief Business Officer. They will have brief prepared remarks, and then we'll open the call for questions. Joining for the Q&A session, we also have Dr. Jim Doherty, our President and Chief Development Officer, and Dr. Eric Siemers, our Chief Medical Officer. Before we begin, we encourage listeners to go to the Investors section of the Acumen website to find our press release issued this morning that we'll discuss today. Please note that during today's conference call, we may make forward-looking statements within the meaning of the federal securities laws, including statements concerning our financial outlook and expected business plans. You will see Slide 2 of our corporate presentation, our press release issued this morning, and our most recent annual and quarterly reports filed with the SEC for important risk factors that could cause our actual results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to update or revise the information provided on this call or in the accompanying presentation as a result of new information or future results or developments. So with that, I'll turn the call over to Dan. Daniel O'Connell: Great. Thanks, Alex. Good morning, everyone, and thanks for joining us today. During the second quarter, our focus remained on disciplined execution as we advanced sabirnetug towards the highly anticipated topline readout from our Phase II ALTITUDE-AD trial, which we continue to expect late this year. We believe this will be an important efficacy readout in the Alzheimer's field. ALTITUDE-AD remains a critical test of our central scientific thesis that selectively targeting synaptotoxic amyloid-beta oligomers may offer a differentiated approach to treating Alzheimer's disease. A substantial body of evidence supports this hypothesis, and we are excited by the opportunity to evaluate that thesis in a well-powered, randomized Phase II study with clinically meaningful endpoints. Our Phase II results have the potential to substantially expand on our Phase I results, which included demonstration of A-beta oligomer t arget engagement and biomarker changes that we're seeing as early as 3 months of treatment, as we previously reported. We continue to be encouraged with the engagement of patients, caregivers, investigators, and study sites participating in ALTITUDE-AD, as well as in its 12-month open-label extension study. Their commitment has …

Leadership Team of ABOS

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Daniel J. O'Connell	Chief Executive Officer & Director	USD 972,747	Male	1970	Active
James Doherty	President & Chief Development Officer	USD 764,370	—	1968	Active
Derek Meisner	Chief Legal Officer & Corporate Secretary	USD 752,945	Male	1971	Active
Matt Zuga	Chief Financial Officer & Chief Business Officer	USD 681,780	Male	—	Active
Russell Barton	Chief Operating Officer	USD 223,680	Male	1959	Active
Caleb E. Finch	Co-Founder	USD 42,000	—	—	Active
Grant A. Krafft	Co-Founder	USD 42,000	—	—	Active
William L. Klein	Co-Founder	USD 42,000	—	—	Active
Alex Braun	Vice President & Head of Investor Relations	—	Female	—	Active
Kelly Carranza	Senior Vice President of Finance & Accounting and Corporate Controller	—	Female	—	Active

Recent News of ABOS

Seeking Alpha8/12/2026Neutral

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript

MarketBeat8/12/2026Neutral

Acumen Pharmaceuticals Q2 Earnings Call Highlights

Acumen Pharmaceuticals NASDAQ: ABOS said it remains on track to report top-line results late in 2026 from its Phase II ALTITUDE-AD study of sabirnetug, an investigational antibody designed to selectively target synaptotoxic amyloid-beta oligomers in early Alzheimer's disease.

GlobeNewsWire8/12/2026Neutral

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights

NEWTON, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the second quarter of 2026 and provided a business update.

GlobeNewsWire8/5/2026Neutral

Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026

NEWTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report second quarter financial results on Wednesday, Aug. 12, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

Zacks Investment Research7/31/2026Neutral

Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.

Historical Employee Count of ABOS

Current

Change

-1.64%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	60	10-K	Mar 26, 2026	View
Dec 31, 2024	61	10-K	Mar 27, 2025	View
Dec 31, 2023	51	10-K	Mar 26, 2024	View
Dec 31, 2022	39	10-K	Mar 27, 2023	View
Dec 31, 2021	14	10-K	Mar 28, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Acumen Pharmaceuticals, Inc.